Synergistic targeting of breast cancer stem-like cells by human gammadelta T cells and CD8+ T cells
Details
Publication Year 2017,Volume 95,Issue #7,Page 620-629
Journal Title
Immunology and Cell Biology
Publication Type
Journal Article
Abstract
The inherent resistance of cancer stem cells (CSCs) to existing therapies has largely hampered the development of effective treatments for advanced malignancy. To help develop novel immunotherapy approaches that efficiently target CSCs, an experimental model allowing reliable distinction of CSCs and non-CSCs was set up to study their interaction with non-MHC restricted gammadelta T cells and antigen-specific CD8+ T cells. Stable lines with characteristics of breast CSC-like cells were generated from ras-transformed human mammary epithelial (HMLER) cells as confirmed by their CD44hi CD24lo GD2+ phenotype, their mesenchymal morphology in culture and their capacity to form mammospheres under non-adherent conditions, as well as their potent tumorigenicity, self-renewal and differentiation in xenografted mice. The resistance of CSC-like cells to gammadelta T cells could be overcome by inhibition of farnesyl pyrophosphate synthase (FPPS) through pretreatment with zoledronate or with FPPS-targeting shRNA. gammadelta T cells induced upregulation of MHC class I and CD54/ICAM-1 on CSC-like cells and thereby increased the susceptibility to antigen-specific killing by CD8+ T cells. Alternatively, gammadelta T cell responses could be specifically directed against CSC-like cells using the humanised anti-GD2 monoclonal antibody hu14.18K322A. Our findings identify a powerful synergism between MHC-restricted and non-MHC restricted T cells in the eradication of cancer cells including breast CSCs. Our research suggests that novel immunotherapies may benefit from a two-pronged approach combining gammadelta T cell and CD8+ T cell targeting strategies that triggers effective innate-like and tumour-specific adaptive responses.Immunology and Cell Biology accepted article preview online, 30 March 2017. doi:10.1038/icb.2017.21.
Publisher
Springer Nature
Research Division(s)
Molecular Genetics Of Cancer
PubMed ID
28356569
Open Access at Publisher's Site
https://doi.org/10.1038/icb.2017.21
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2017-04-12 10:36:13
Last Modified: 2018-05-04 11:58:16
An error has occurred. This application may no longer respond until reloaded. Reload 🗙